Autopsy report · NCT02822716

Irreversible Electroporation for Inoperable Hepatic and Pancreatic Malignancy

“poor case accural”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 11 months after it had already started.
• Ran for about 7 years 2 months before it stopped.
• 11 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Chinese University of Hong Kong

Sponsor type

University, hospital or other

Conditions

Hepatic Malignant Tumors; Pancreatic Cancer

Interventions

IRE treatment; Ultrasound

Participants

11

Sites

1

Countries

Hong Kong

Trials that died the same way

• Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus
  “adequate cases were not available” (65% match in meaning)
• LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer
  “Poor accrual” (60% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.